
WHAT IS CLAIMED IS:

1 . A compound having formula (I):




2

3 (I)

4 or a tautomer thereof or a pharmaceutically acceptable salt thereof,

5 wherein:

6 Y^1 is selected from the group consisting of:



7 and  ;

8 Z is O or S;

9 D^1 is selected from the group consisting of:

10 (a) phenyl substituted with a group, R^5, wherein the phenyl is further

11 optionally substituted with from 1 to 2 substituents, R^{7a}, independently selected from the

12 group consisting of $C_{1\text{-}8}$alkyl, $C_{1\text{-}8}$alkoxy, halo, $C_{1\text{-}8}$alkylsulfonyl and heterocyclyl;

13 R^5 is selected from the group consisting of:

14 (i) heteroaryl;

15 (ii) heterocyclyl;

16 (iii) $C_{1\text{-}8}$alkyleneheterocyclyl;

17 (iv) phenyleneheteroaryl

18 (v) phenyleneheterocyclyl

19 (vi) –L-phenyl;

20 (vii) –L-heterocyclyl; and

21 (viii) acetoxy;

22 L is selected from the group consisting of –CO-, -O-, $-SO_2$-, -CONH- and –

23 $CONHCH_2$-;

each R^5 is optionally further substituted with from 1 to 2 substituents independently selected from the group consisting of C_{1-8}alkyl, hydroxyC_{1-8}alkyl-, aminoC_{1-8}alkyl, C_{1-8}alkylamino, C_{1-8}alkylcarbonyl, aminocarbonyl, cyano, hydroxy, oxo, halo, haloC_{1-8}alkyl, aminosulfonyl, C_{3-8}cycloalkyl and aryl;

(b) naphthyl substituted a substituent , R^{7b}, selected from the group consisting of halogen, C_{1-8}alkylcarbonyl, C_{1-8}alkylsulfonyl, aminosulfonyl, heterocyclylcarbonyl and aminocarbonyl;

(c) C_{3-8}cycloalkyl, optionally substituted with from 1 to 2 substituents, R^{7c}, independently selected from the group consisting of C_{1-8}alkyl, C_{1-8}alkoxy, halo, C_{1-8}alkylsulfonyl and heterocyclyl;

(d) heteroaryl; optionally substituted with from 1 to 2 substituents, R^{7d}, independently selected from the group consisting of: C_{1-8} alkyl, amino, hydroxyl, oxo, halo, C_{1-8} alkoxy, hydroxyC_{1-8}alkyl-, aminoC_{1-8}alkyl, C_{1-8}alkylcarbonyl, haloC_{1-8}alkyl, C_{3-8}cycloalkyl, C_{1-8}aminocycloalkyl, aminoC_{1-8}alkylenecarbonyl, aminocarbonyl, C_{1-8}alkyleneaminoC_{1-8}alkylenecarbonyl, C_{1-8}alkoxyC_{1-8}alkylenecarbonyl, hydroxyC_{1-8}alkylenecarbonyl, hydroxyC_{1-8}alkoxycarbonyl, C_{1-8} alkoxycarbonylamino, aryl, arylC_{1-8} alkoxycarbonylamino, C_{1-8}alkylsulfonyl, aminoC_{1-8}alkylenesulfonyl, aminosulfonyl, C_{1-8}alkyleneaminoC_{1-8}alkylenesulfonyl, C_{1-8}alkoxyC_{1-8}alkylenesulfonyl, hydroxyC_{1-8}alkylenesulfonyl, hydroxyC_{1-8}alkoxysulfonyl, aminosulfonyl, and C_{1-8}alkylheterocyclyl; and

(e) heterocyclyl; with from 1 to 2 substituents, R^{7e}, independently selected from the group consisting of C_{1-8}alkyl, C_{1-8}alkoxy, halo, C_{1-8}alkylsulfonyl and heterocyclyl;

each E^1 is independently selected from the group consisting of C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8}alkynyl, C_{1-8}alkoxy, C_{1-8}alkylthio, aminocarbonyl, C_{1-8}alkoxycarbonylC_{1-8}alkylene, C_{1-8}alkoxycarbonyl$C_{1-8}C_{1-8}$alkoxy, C_{1-8}alkoxycarbonylamino, oxo, halo, cyano, haloC_{1-8}alkyl, haloC_{1-8}alkoxy, aminosulfonyl, heteroarylsulfinyl; amino, hydroxyl, C_{1-8}arylalkylene, phenyl, aminoC_{1-8}alkyl, aminoC_{3-8}cycloalkyl, heterocyclyl, heteroaryl and heterocyclylC_{1-8}alkylene;

each R^{1a}, R^{1b} and R^{1c} is independently selected from the group consisting of: H, C_{1-8}alkyl, hydroxyC_{1-8}alkyl, C_{1-8}haloalkyl, amino, C_{1-8}alkylamino, C_{1-8} alkoxycarbonylaminoC_{1-8} alkylene, C_{3-8}cycloalkyl, heteroaryl, C_{1-8} alkylC_{3-8}cycloalkyl, C_{1-8}alkylthioC_{1-8} alkyl, C_{1-8}alkylsulfonylC_{1-8} alkylene, aminocarbonyl, C_{1-8}alkoxyC_{1-8}alkyl, haloC_{1-8}alkyl, aryl and heterocyclyl; wherein the aryl is optionally substituted by hydroxyl, C_{1-8}alkoxy, halo or haloC_{1-8}alkyl; or taken together with R^3 and the atoms to which they are attached to form a C_{3-8} cycloalkyl or hetercycloalkyl ring;

R^2 is selected from the group consisting of H, amino, $C_{1\text{-}8}$alkylamino, hydroxycarbonylamino $C_{1\text{-}8}$alkoxycarbonylamino ,aryl$C_{1\text{-}8}$alkoxycarbonylamino and hydroxyl;


R^3 is selected from the group consisting of H, $C_{1\text{-}8}$alkyl, $C_{1\text{-}8}$alkylamino, amino, amino$C_{1\text{-}8}$alkyl, carboxy, $C_{1\text{-}8}$alkylamino$C_{1\text{-}8}$alkyl, $C_{1\text{-}8}$alkoxy$C_{1\text{-}8}$alkyl, hydroxy$C_{1\text{-}8}$alkyl; carboxy$C_{1\text{-}8}$alkyl, $C_{3\text{-}8}$cycloalkyl$C_{1\text{-}8}$alkyl, aryloxy$C_{1\text{-}8}$alkyl, aryl$C_{1\text{-}8}$alkyl, heteroaryl$C_{1\text{-}8}$alkyl, and hydroxy$C_{1\text{-}8}$alkoxy and hydroxy$C_{1\text{-}8}$alkoxy; or may be combined with R^{1c} or R^4 and the atoms to which they are attached to form a $C_{3\text{-}8}$ cycloalkyl or heterocyclyl ring;

R^4 is H or alkyl or may be combined with R^3 and the atoms to which they are attached to form a $C_{3\text{-}8}$ cycloalkyl or heterocyclyl ring;


the subscript n is 0, 1, 2, 3 or 4; and

the subscript m is an integer of 1, 2 or 3; and the wavy line indicates the point of attachment to the rest of the molecule.

2. The compound of claim 1 wherein Y^1 is:



3. The compound of claim 1 wherein Y^1 is:



4. The compound of any of the preceding claims wherein Z is S.

5. The compound of any of the preceding claims wherein Z is O.

6. The compound of any of claims 1 to 3 wherein Z is S.

7. The compound of any of the preceding claims wherein D^1 is phenyl.

8. The compound of claim 7, wherein R^5 is heteroaryl.

9. The compound of claim 7, wherein R^5 is heterocyclyl.

10. The compound of claim 7, wherein R^5 is $C_{1\text{-}8}$alkyleneheterocyclyl.

11. The compound of claim 7, wherein R^5 is phenyleneheteroaryl.

12. The compound of claim 7, wherein R^5 is phenyleneheterocyclyl.

13. The compound of claim 7, wherein R^5 is –L-phenyl.

14. The compound of claim 7, wherein R^5 is–L-heterocyclyl.

15. The compound of claim 13 or 14, wherein L is –CO-.

16. The compound of claim 13 or 14, wherein L is -O-.

17. The compound of claim 13 or 14, wherein L is -SO_2-.



18. The compound of claim 13 or 14, wherein L is -CONH-.


19. The compound of claim 13 or 14, wherein L is –$CONHCH_2$-.

20. The compound of claim 7, wherein R^5 is acetoxy.

21. The compound of any of claims 1 to 3 wherein D^1 is naphthyl.

22. A compound f any of claims 1 to 3, wherein D^1- is selected from the group consisting of:



and


; and

X is halogen.



23. The compound of any of claims 1 to 3 wherein D^1 is $C_{3\ 8}$cycloalkyl.

24. The compound of claim 1 to 3, wherein D^1 is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

25. The compound of any of claims 1 to 3 wherein D^1 is heteroaryl.


26. The compound of any of claims 1 to 3 wherein D^1 is heterocyclyl.

27. The compound of any of the preceding claims wherein the heteroaryl group, alone or when part of a group containing a heteroaryl moiety is selected from the group consisting of:

and ; each of which is optionally substituted with from 1 to 2 substituents independently selected from the group consisting of: C_{1-8} alkyl, amino, hydroxyl, oxo, halo, C_{1-8} alkoxy, hydroxyC_{1-8}alkyl-, aminoC_{1-8}alkyl, C_{1-8}alkylcarbonyl, haloC_{1-8}alkyl, C_{3-8}cycloalkyl, C_{1-8}aminocycloalkyl, aminoC_{1-8}alkylenecarbonyl, aminocarbonyl, C_{1-8}alkyleneaminoC_{1-8}alkylenecarbonyl, C_{1-8}alkoxyC_{1-8}alkylenecarbonyl, hydroxyC_{1-8}alkylenecarbonyl, hydroxyC_{1-8}alkoxycarbonyl, C_{1-8} alkoxycarbonylamino, aryl, arylC_{1-8} alkoxycarbonylamino, C_{1-8}alkylsulfonyl, aminoC_{1-8}alkylenesulfonyl, aminosulfonyl, C_{1-8}alkyleneaminoC_{1-8}alkylenesulfonyl, C_{1-8}alkoxyC_{1-8}alkylenesulfonyl, hydroxyC_{1-8}alkylenesulfonyl, hydroxyC_{1-8}alkoxysulfonyl, aminosulfonyl, and C_{1-8}alkylheterocyclyl.


28. The compound of any of the preceding claims wherein the heteroaryl group, alone or when part of a group containing a heteroaryl moiety is selected from the group consisting of:



optionally substituted with from 1 to 3 R^{7d} substituents independently selected from the group consisting of: C_{1-8} alkyl, C_{1-8}alkylcarbonyl, C_{1-8}aminocycloalkyl, aminoC_{1-8}alkylenecarbonyl, aminocarbonyl, C_{1-8}alkyleneaminoC_{1-8}alkylenecarbonyl, C_{1-8}alkoxyC_{1-8}alkylenecarbonyl, hydroxyC_{1-8}alkylenecarbonyl, hydroxyC_{1-8}alkoxycarbonyl, aminocarbonyl, amino, C_{1-8} alkoxycarbonylamino, aryl, arylC_{1-8} alkoxycarbonylamino, hydroxyl, C_{1-8} alkoxy, C_{1-8}alkylsulfonyl, aminoC_{1-8}alkylenesulfonyl, aminosulfonyl, C_{1-8}alkyleneaminoC_{1-8}alkylenesulfonyl, C_{1-8}alkoxyC_{1-8}alkylenesulfonyl,


hydroxyC_{1-8}alkylenesulfonyl, hydroxyC_{1-8}alkoxysulfonyl, aminosulfonyl, oxo, halo, phenyl and C_{1-8}alkylheterocyclyl; and the wavy line indicates the point of attachment to the rest of the molecule.

29. A compound of any of claims 1 to 3, wherein R^5 is selected from the group consisting of




each of which is optionally substituted with from 1 to 2 substituents independently selected from the group consisting of C_{1-8}alkyl, hydroxyC_{1-8}alkyl-, aminoC_{1-8}alkyl, C_{1-8}alkylcarbonyl, aminocarbonyl, hydroxy, oxo, halo, haloC_{1-8}alkyl, aminosulfonyl and C_{3-8}cycloalkyl.

30. A compound of claim 29 wherein R^5 is selected from the group consisting of



; each of which is optionally substituted with from 1 to 2 substituents independently selected from the group consisting of C_{1-8}alkyl, hydroxyC_{1-8}alkyl-, aminoC_{1-8}alkyl, C_{1-8}alkylcarbonyl, aminocarbonyl, hydroxy, oxo, halo, haloC_{1-8}alkyl, aminosulfonyl and C_{3-8}cycloalkyl.


31. A compound of claim 29 wherein R^5 is selected from the group consisting of





and

32. The compound of any of claims 1 to 3, wherein: D^1 is bicyclic heteroaryl.

33. The compound of claim 32, wherein D^1 is selected from the group consisting of:









and ,


optionally substituted with from 1 to 3 R^{7d} substituents independently selected from the group consisting of: C_{1-8} alkyl, C_{1-8}alkylcarbonyl, aminoC_{1-8}alkylenecarbonyl, aminocarbonyl, C_{1-8}alkyleneaminoC_{1-8}alkylenecarbonyl, C_{1-8}alkoxyC_{1-8}alkylenecarbonyl, hydroxyC_{1-8}alkylenecarbonyl, hydroxyC_{1-8}alkoxycarbonyl, aminocarbonyl, amino, C_{1-8} alkoxycarbonylamino, arylC_{1-8} alkoxycarbonylamino, hydroxyl, C_{1-8} alkoxy, C_{1-8}alkylsulfonyl, aminoC_{1-8}alkylenesulfonyl, aminosulfonyl, C_{1-8}alkyleneaminoC_{1-8}alkylenesulfonyl, C_{1-8}alkoxyC_{1-8}alkylenesulfonyl, hydroxyC_{1-8}alkylenesulfonyl, hydroxyC_{1-8}alkoxysulfonyl, aminosulfonyl, oxo, halo, phenyl and C_{1-8}alkylheterocyclyl; and the wavy line indicates the point of attachment to the rest of the molecule.



34. A compound of claim 33, wherein D^1 is selected from the group consisting of:













and






; and the wavy line indicates the point of attachment to the rest of the molecule.




35. The compound of claim 34, wherein D^1 is selected from the group consisting of:



and




; and the wavy line indicates the point of attachment to the rest of the molecule.

36. A compound of claim 34, wherein D^1 is selected from the group consisting of:




and ; and the wavy line indicates the point of attachment to the rest of the molecule.

37. A compound of claim 36, selected from the group consisting of:





and .

38. The compound of any of claims 1 to 3, wherein each E^1 is independently selected from the group consisting of C_{1-8}alkyl, heteroaryl, heterocyclyl, halo, C_{1-8}haloalkyl, C_{1-8}alkoxy, C_{1-8}acyl, aminoC_{1-8}alkyl, aminosulfonyl, C_{1-8}alkylsulfonyl and acylamino.

39. The compound of claim 38 wherein each E^1 is independently selected from the group consisting of




40. The compound of claim 38 wherein each E^1 is independently selected from the group consisting of



and

.

41. The compound of any of the preceding claims, wherein R^2 is amino.

42. The compound of claim 2, wherein: the moiety:




is



;

wherein X and Y is each independently selected from the group consisting of: CH_2, NH, $NCOCH_3$ and S.

43. The compound of claim 2, wherein the moiety:




is selected from the group consisting of:


;


wherein each R^{8a} and R^{8b} is independently H, hydroxyl, halo or if on adjacent carbon atoms, may be combined with the atoms to which they are attached to form a fused benzene ring; and

each R^{9a} and R^{9b} is independently H, hydroxyl, halo or, if on adjacent carbon atoms, may be combined with the atoms to which they are attached to form a fused benzene ring; and the wavy line indicates the point of attachment to the rest of the molecule.


44. The compound of claim 2, wherein: the moiety:



is




or



;

wherein each R^{8a} and R^{8b} is independently H or may be combined with the atoms to which they are attached to form a fused benzene ring; and the wavy line indicates the point of attachment to the rest of the molecule.


45. The compound of claim 2 wherein the compound has the formula:



;


wherein each X and Y is independently selected from the group consisting of: CH_2, NH, $NCOCH_3$ and S.

46. The compound of claim 2 wherein the compound has the formula:



2


1 47. The compound of claim 2 wherein the compound has the formula:



2 ;




3 wherein each X and Y is independently selected from the group consisting of:
4 CH_2, NH, $NCOCH_3$ and S.

1 48. The compound of claim 2 wherein the compound has the formula:




2 ..

1 49. The compound of claim 2 wherein the compound has the formula:


, 
and 
.


2

50. The compound of claim 2 wherein the compound has the formula selected from the group consisting of:



..


51. The compound of claim 2 wherein the compound has the formula selected from the group consisting of:



;


wherein each X and Y is independently selected from the group consisting of: CH_2, NH, $NCOCH_3$ and S.

52. The compound of claim 2 wherein the compound has the formula selected from the group consisting of:





..




53. The compound of claim 2 wherein the compound has the formula:



2  ;


3 wherein each X and Y is independently selected from the group consisting of:
4 CH_2, NH, $NCOCH_3$ and S.

5 54. The compound of claim 46, selected from the group consisting of:




6  ,  ,




7  ,  ,  ,




8  ,  and




9  .




55. The compound of claim 46, selected from the group consisting of:





,

,

,





,

,

,





,

,

,





,

,

,





,

,

,

7  ,  ,  ,


8  ,  ,  ,

9  ,  ,  ,



10  ,  ,  ,

and




56. A compound of claim 54, having the formula:





or


57. A compound of claim 54, having the formula:




58. A compound of claim 54, having the formula:



59. The compound of claim 3, wherein the moiety:




is




and the wavy line indicates the point of attachment to the rest of the molecule.



60. The compound of claim 59 wherein a compound having the formula:




61. The compound of claim 59 wherein the compound has the formula:




62. The compound of claim 59 wherein the compound has a formula selected from the group consisting of:



and





63. The compound of claim 59 wherein R^{1a} is selected from the group consisting of $C_{1\text{-}8}$alkyl, $C_{3\text{-}8}$cycloalkyl, aryl, heteroaryl and heterocyclyl.

64. The compound of claim 2, wherein the moiety:




is selected from the group consisting of:





65. A compound having the structure selected from the group consisting of formula IIa-c:



IIa IIb IIc


or a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein:

E^{2a} is selected from the group consisting of C_{1-8} alkoxy, C_{1-8}alkylC_{3-8}cycloalkylcarbonylamino, C_{1-8}alkoxyC_{1-8}alkylenecarbonylamino-, C_{1-8}alkoxycarbonylamino and C_{1-8}alkylcarbonylamino;

R^3 is selected from the group consisting of H, halo, C_{1-8}alkyl and C_{1-8}alkoxy; and

R^4 is selected from the group consisting of H, C_{1-8}alkyl and C_{1-8}alkoxy C_{1-8}alkylene.

66. A compound having formula (IId):




(IId)


or a tautomer thereof or a pharmaceutically acceptable salt thereof,

wherein R^3 is H or C_{1-8}alkyl.

67. A compound having formula:



68. A compound having formula (IIe):




(IIe)

wherein: D^2 is a bicyclic aryl group.

69. The compound of claim 68, wherein: D^2 is naphthyl, optionally substituted with from 1 to 2 substituents, E^{2b}, independently selected from the group consisting of halo, C_{1-8}alkoxy and C_{1-8}alkylaminocarbonyl.


70. A compound of claim 68, wherein D^2 is



;


and the wavy line indicates the point of attachment to the rest of the molecule.

71. A compound of claim 68, wherein D^2 is


;

and the wavy line indicates the point of attachment to the rest of the molecule..


72. A compound of claim 68, wherein D^2 is selected from the group consisting of:



and ;

and the wavy line indicates the point of attachment to the rest of the molecule.

73. A compound of claim 68, having the formula



74. A compound having a structure found in the Examples.

75. A compound having a structure found in the Tables.

76. A compound having a structure found in the Figures.

77. A composition comprising a compound of any of the preceding claims in combination with a pharmaceutically acceptable carrier or diluent.

78. A method for inhibiting syk or JAK kinase or a signal transduction pathway mediated at least in part by syk kinase activity comprising the step of contacting a cell with a compound of any one of the preceding claims.

79. A method for treating a condition or disorder mediated at least in part by syk kinase activity in a subject comprising the step of administering to a subject in need of such treatment a therapeutically effective amount of a composition of claim 77.

80. The method of claim 79, wherein the condition or disorder is selected from the group consisting of cardiovascular disease, inflammatory disease and autoimmune disease and cell proliferative disorder.

81. The method of claim 79, wherein said cardiovascular disease is selected from the group consisting of restenosis, thrombosis, immune thrombocytopenic purpura, heparin induced thrombocytopenia, dilated cardiomyopathy, sickle cell disease, atherosclerosis, myocardial infarction, vascular inflammation, unstable angina and acute coronary syndromes.

82. The method of claim 79, wherein said inflammatory disease is selected from the group consisting of allergy, asthma, rheumatoid arthritis, B Cell mediated diseases such as Non Hodgkin's Lymphoma, anti phospholipid syndrome, lupus, psoriasis, multiple sclerosis and end stage renal disease.

83. The method of claim 79, wherein said cardiovascular disease is selected from the group consisting of thrombosis, immune thrombocytopenic purpura, and heparin induced thrombocytopenia.

84. The method of claim 79, wherein said inflammatory disease is rheumatoid arthritis or Non Hodgkin's Lymphoma.

85. The method of claim 79, wherein said sickle cell disease is selected from the group consisting of sickle cell anemia, sickle-hemoglobin C disease, sickle beta-plus thalassemia, and sickle beta-zero thalassemia.

86. The method of claim 79, wherein said immune-related disease is selected from the group consisting of a T-cell mediated disease, an autoimmune disease, host versus graft rejection, graft versus host rejection, a Type IV hypersensitivity reaction and allograft rejection.

87. The method of claim 79, wherein said autoimmune disease is selected from the group consisting of hemolytic anemia, immune thrombocytopenic purpura, multiple sclerosis, Sjogren's syndrome. diabetes, rheumatoid arthritis, lupus and psoriasis.


88. The method of claim 79, wherein said wherein said cell proliferative disorder is leukemia, a lymphoma, myeloproliferative disorders, hematological malignancies, and chronic idiopathic myelofibrosis.

89. The method of claim 79, wherein said disorder is acute myeloid leukemia, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma.

90. A kit comprising a composition of claim 77, packaging and instructions for use.

CLAIMS

1. A compound having formula (I):



(I)


or a tautomer thereof or a pharmaceutically acceptable salt thereof,

wherein:

D^1 is phenyl substituted with heteroaryl;


each E^1 is independently selected from the group consisting of C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8}alkynyl, C_{1-8}alkoxy, C_{1-8}alkylthio, aminocarbonyl, C_{1-8}alkoxycarbonylC_{1-8}alkylene, C_{1-8}alkoxycarbonyl$C_{1-8}C_{1-8}$alkoxy, C_{1-8}alkoxycarbonylamino, oxo, halo, cyano, haloC_{1-8}alkyl, haloC_{1-8}alkoxy, aminosulfonyl, heteroarylsulfinyl; amino, hydroxyl, C_{1-8}arylalkylene, phenyl, aminoC_{1-8}alkyl, aminoC_{3-8}cycloalkyl, heterocyclyl, heteroaryl, C_{1-8}acyl, C_{1-8}alkylsulfonyl, acylamino and heterocyclylC_{1-8}alkylene;

the moiety:



is either:





(a)



; and

wherein X and Y is each independently selected from the group consisting of: CH_2, NH, $NCOCH_3$ and S;



(b) selected from the group consisting of:




and

; and

wherein each R^{8a} and R^{8b} is independently H, hydroxyl, halo or if on adjacent carbon atoms, may be combined with the atoms to which they are attached to form a fused benzene ring; and

each R^{9a} and R^{9b} is independently H, hydroxyl, halo or, if on adjacent carbon atoms, may be combined with the atoms to which they are attached to form a fused benzene ring; and the wavy line indicates the point of attachment to the rest of the molecule; or

(c)



or

;


wherein each R^{8a} and R^{8b} is independently H or may be combined with the atoms to which they are attached to form a fused benzene ring; and the wavy line indicates the point of attachment to the rest of the molecule; and

the subscript n is 0, 1, 2, 3 or 4.

2. The compound of claim 1, or a tautomer thereof or a pharmaceutically acceptable salt thereof;


wherein the moiety:


is:



; and

wherein X and Y is each independently selected from the group consisting of: CH_2, NH, $NCOCH_3$ and S.

3. The compound of claim 1 or a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein the moiety:




is selected from the group consisting of:



, , and ;

each R^{8a} and R^{8b} is independently H, hydroxyl, halo or if on adjacent carbon atoms, may be combined with the atoms to which they are attached to form a fused benzene ring; and

each R^{9a} and R^{9b} is independently H, hydroxyl, halo or, if on adjacent carbon atoms, may be combined with the atoms to which they are attached to form a fused benzene ring; and the wavy line indicates the point of attachment to the rest of the molecule.

4. The compound of claim 1 or a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein the moiety:



is:



or ;

wherein each R^{8a} and R^{8b} is independently H or may be combined with the atoms to which they are attached to form a fused benzene ring; and the wavy line indicates the point of attachment to the rest of the molecule.


5. The compound of claim 1 wherein the compound has the formula:



;

or a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein each X and Y is independently selected from the group consisting of: CH_2, NH, $NCOCH_3$ and S.


6. The compound of claim 1 wherein the compound has the formula:



;

or a tautomer thereof or a pharmaceutically acceptable salt thereof.


7. The compound of claim 1 wherein the compound has the formula:



;

or a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein each X and Y is independently selected from the group consisting of: CH_2, NH, $NCOCH_3$ and S; and


R^5 is selected from the group consisting of:



each of which is optionally substituted with from 1 to 2 substituents independently selected from the group consisting of:

C_{1-8} alkyl, amino, hydroxyl, oxo, halo, C_{1-8} alkoxy, hydroxyC_{1-8}alkyl-, aminoC_{1-8}alkyl, C_{1-8}alkylcarbonyl, haloC_{1-8}alkyl, C_{3-8}cycloalkyl, C_{1-8}aminocycloalkyl, aminoC_{1-8}alkylenecarbonyl, aminocarbonyl, C_{1-8}alkyleneaminoC_{1-8}alkylenecarbonyl, C_{1-8}alkoxyC_{1-8}alkylenecarbonyl, hydroxyC_{1-8}alkylenecarbonyl, hydroxyC_{1-8}alkoxycarbonyl, C_{1-8} alkoxycarbonylamino, aryl, arylC_{1-8} alkoxycarbonylamino, C_{1-8}alkylsulfonyl, aminoC_{1-8}alkylenesulfonyl, aminosulfonyl, C_{1-8}alkyleneaminoC_{1-8}alkylenesulfonyl, C_{1-8}alkoxyC_{1-8}alkylenesulfonyl, hydroxyC_{1-8}alkylenesulfonyl, hydroxyC_{1-8}alkoxysulfonyl, aminosulfonyl, and C_{1-8}alkylheterocyclyl.


8. The compound of claim 1 wherein the compound has the formula:



;

or a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein each X and Y is independently selected from the group consisting of: CH_2, NH, $NCOCH_3$ and S;

R^5 is selected from the group consisting of:




optionally substituted with from 1 to 3 R^{7d} substituents independently selected from the group consisting of:

C_{1-8} alkyl, C_{1-8}alkylcarbonyl, C_{1-8}aminocycloalkyl, aminoC_{1-8}alkylenecarbonyl, aminocarbonyl, C_{1-8}alkyleneaminoC_{1-8}alkylenecarbonyl, C_{1-8}alkoxyC_{1-8}alkylenecarbonyl, hydroxyC_{1-8}alkylenecarbonyl, hydroxyC_{1-8}alkoxycarbonyl, aminocarbonyl, amino, C_{1-8} alkoxycarbonylamino, aryl, arylC_{1-8} alkoxycarbonylamino, hydroxyl, C_{1-8} alkoxy, C_{1-8}alkylsulfonyl, aminoC_{1-8}alkylenesulfonyl, aminosulfonyl, C_{1-8}alkyleneaminoC_{1-8}alkylenesulfonyl, C_{1-8}alkoxyC_{1-8}alkylenesulfonyl,

hydroxyC_{1-8}alkylenesulfonyl, hydroxyC_{1-8}alkoxysulfonyl, aminosulfonyl, oxo, halo, phenyl and C_{1-8}alkylheterocyclyl; and the wavy line indicates the point of attachment to the rest of the molecule.


9. The compound of claim 1, wherein the compound has the formula:



;

or a tautomer thereof or a pharmaceutically acceptable salt thereof,


wherein R^5 is selected from the group consisting of:



each of which is optionally substituted with from 1 to 2 substituents independently selected from the group consisting of:

C_{1-8} alkyl, amino, hydroxyl, oxo, halo, C_{1-8} alkoxy, hydroxyC_{1-8}alkyl-, aminoC_{1-8}alkyl, C_{1-8}alkylcarbonyl, haloC_{1-8}alkyl, C_{3-8}cycloalkyl, C_{1-8}aminocycloalkyl, aminoC_{1-8}alkylenecarbonyl, aminocarbonyl, C_{1-8}alkyleneaminoC_{1-8}alkylenecarbonyl, C_{1-8}alkoxyC_{1-8}alkylenecarbonyl, hydroxyC_{1-8}alkylenecarbonyl, hydroxyC_{1-8}alkoxycarbonyl, C_{1-8} alkoxycarbonylamino, aryl, arylC_{1-8} alkoxycarbonylamino, C_{1-8}alkylsulfonyl, aminoC_{1-8}alkylenesulfonyl, aminosulfonyl, C_{1-8}alkyleneaminoC_{1-8}alkylenesulfonyl, C_{1-8}alkoxyC_{1-8}alkylenesulfonyl, hydroxyC_{1-8}alkylenesulfonyl, hydroxyC_{1-8}alkoxysulfonyl, aminosulfonyl, and C_{1-8}alkylheterocyclyl.


10. The compound of claim 1, wherein the compound has the formula:



;

or a tautomer thereof or a pharmaceutically acceptable salt thereof,

R^5 is selected from the group consisting of:




optionally substituted with from 1 to 3 R^{7d} substituents independently selected from the group consisting of:

C_{1-8} alkyl, C_{1-8}alkylcarbonyl, C_{1-8}aminocycloalkyl, aminoC_{1-8}alkylenecarbonyl, aminocarbonyl, C_{1-8}alkyleneaminoC_{1-8}alkylenecarbonyl, C_{1-8}alkoxyC_{1-8}alkylenecarbonyl, hydroxyC_{1-8}alkylenecarbonyl, hydroxyC_{1-8}alkoxycarbonyl, aminocarbonyl, amino, C_{1-8} alkoxycarbonylamino, aryl, arylC_{1-8} alkoxycarbonylamino, hydroxyl, C_{1-8} alkoxy, C_{1-8}alkylsulfonyl, aminoC_{1-8}alkylenesulfonyl, aminosulfonyl, C_{1-8}alkyleneaminoC_{1-8}alkylenesulfonyl, C_{1-8}alkoxyC_{1-8}alkylenesulfonyl, hydroxyC_{1-8}alkylenesulfonyl, hydroxyC_{1-8}alkoxysulfonyl, aminosulfonyl, oxo, halo, phenyl and


C_{1-8}alkylheterocyclyl; and the wavy line indicates the point of attachment to the rest of the molecule.

11. The compound of claim 9 or 10 wherein the compound has the formula:




or a tautomer thereof or a pharmaceutically acceptable salt thereof.

12. The compound of claim 7 or 8 wherein the compound has the formula:



or a tautomer thereof or a pharmaceutically acceptable salt thereof.

13. The compound of claim 11 wherein the compound has the formula selected from the group consisting of:



14. The compound of claim 1, selected from the group consisting of: 4-(4-(1H-pyrazol-1-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide; 4-(4-(1,2,3-thiadiazol-4-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(pyridin-4-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(pyridin-3-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(pyridin-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(pyrimidin-5-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(thiazol-4-yl)phenylamino)pyrimidine-5-carboxamide; 4-(4-(1,2,3-thiadiazol-4-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(pyridin-3-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(pyrimidin-5-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(pyridin-4-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(thiazol-5-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(thiazol-2-yl)phenylamino)pyrimidine-5-carboxamide; 4-(4-(1H-pyrazol-1-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(pyridin-3-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(pyrimidin-5-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(pyridazin-4-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(pyrazin-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(pyridin-4-yl)phenylamino)pyrimidine-5-carboxamide; 4-(4-(1H-1,2,3-triazol-1-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(1-methyl-1H-imidazol-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(2-oxopyridin-1(2H)-yl)phenylamino)pyrimidine-5-carboxamide; 4-(4-(1H-imidazol-1-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(3-(trifluoromethyl)-1H-pyrazol-1-yl)phenylamino)pyrimidine-5-carboxamide; 4-(3-(1H-

pyrazol-1-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-fluoro-4-(1H-pyrazol-1-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-fluoro-4-(thiazol-4-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-fluoro-4-(1H-imidazol-1-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-fluoro-4-(4-methyl-1H-pyrazol-1-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(2-fluoro-4-(1H-pyrazol-1-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(thiazol-4-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(2-fluoro-4-(thiazol-4-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(thiazol-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(thiazol-5-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(pyridin-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(pyrazin-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(pyridazin-4-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(1-methyl-1H-imidazol-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(6-methoxypyridin-3-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(6-methoxypyridin-3-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(2-aminopyridin-4-yl)phenylamino)pyrimidine-5-carboxamide; 4-(4-(1H-1,2,4-triazol-1-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexyl-amino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(isoxazol-5-yl)phenylamino)pyrimidine-5-carboxamide; 4-(4-(1H-tetrazol-1-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(oxazol-5-yl)phenylamino) pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(oxazol-4-yl)phenylamino) pyrimidine-5-carboxamide; 4-(3-(1H-1,2,4-triazol-1-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino) pyrimidine 5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(5-methyl-1,2,4-oxadiazol-3-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-

4-(3-(2-methylthiazol-4-yl)phenylamino) pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenylamino) pyrimidine-5-carboxamide; 4-(3-(1H-pyrazol-5-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexyl amino) pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(thiophen-2-yl)phenylamino) pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-methoxy-4-(oxazol-5-yl)phenylamino) pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(3-methyl-1H-pyrazol-1-yl)phenylamino) pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(3,5-dimethyl-1H-pyrazol-1-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-methoxy-5-(1H-tetrazol-1-yl)phenylamino)pyrimidine-5-carboxamide; 4-(3-(1H-tetrazol-1-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexyl amino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(5-methyl-1H-tetrazol-1-yl)phenylamino) pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(1-methyl-1H-tetrazol-5-yl) phenylamino) pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenylamino) pyrimidine-5-carboxamide; 4-(3-(1H-pyrrol-1-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino) pyrimidine-5-carboxamide; 4-(4-(1H-pyrrol-1-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino) pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(5-methylfuran-2-yl)phenylamino) pyrimidine-5-carboxamide; 4-(4-(1,3,4-oxadiazol-2-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexyl amino)pyrimidine-5-carboxamide; 4-(3-(2H-tetrazol-5-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexyl amino) pyrimidine-5-carboxamide; 4-(4-(2H-tetrazol-5-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexyl amino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-fluoro-4-(3-(trifluoromethyl)-1H-pyrazol-1-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3,4-bis(3-(trifluoromethyl)-1H-pyrazol-1-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-morpholino-4-(1H-pyrazol-1-yl)phenylamino)pyrimidine-5-carboxamide; 4-(3-(1H-imidazol-1-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-


aminocyclohexylamino)-4-(4-(2-methyl-1H-imidazol-1-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(2-methyl-1H-imidazol-1-yl)phenylamino)pyrimidine-5-carboxamide; 4-(3-(1H-1,2,3-triazol-1-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide; 4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(4-(aminomethyl)-1H-1,2,3-triazol-1-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(4-carbamoyl-1H-1,2,3-triazol-1-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-fluoro-3-(2H-1,2,3-triazol-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-cyano-3-(2H-1,2,3-triazol-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-cyano-5-(2H-1,2,3-triazol-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-cyano-5-(1H-1,2,3-triazol-1-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(6-methoxypyridin-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(4-methoxypyrimidin-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(5-fluoropyrimidin-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(4-methyl-1H-1,2,3-triazol-1-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(4-methyl-2H-1,2,3-triazol-2-yl)phenylamino)pyrimidine-5-carboxamide; 4-(3-(2H-tetrazol-2-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-methyl-5-(2H-tetrazol-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(4-methyl-4H-1,2,4-triazol-3-yl)phenylamino)pyrimidine-5-carboxamide; 4-(3-(1H-benzo[d]imidazol-1-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide; 4-(3-(1H-indazol-1-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide (242.A) and 4-(3-(2H-indazol-2-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide (242.B); 4-(3-

(1H-benzo[d][1,2,3]triazol-1-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide (243.A) and 4-(3-(2H-benzo[d][1,2,3]triazol-2-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide (243.B); 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(imidazo[1,2-a]pyridin-2-yl)phenylamino)pyrimidine-5-carboxamide; 4-(3-(2H-benzo[b][1,4]oxazin-4(3H)-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(quinolin-6-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(quinolin-3-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(1-methyl-1H-pyrazol-3-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(1-methyl-1H-pyrazol-4-yl)phenylamino)pyrimidine-5-carboxamide; 4-(4-(2H-1,2,3-triazol-2-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-fluoro-5-(2H-1,2,3-triazol-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-methoxy-3-(2H-1,2,3-triazol-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-methoxy-5-(2H-1,2,3-triazol-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-methyl-3-(2H-1,2,3-triazol-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-methyl-5-(2H-1,2,3-triazol-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(pyrimidin-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(pyrimidin-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(1-methyl-1H-pyrazol-3-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(1-methyl-1H-pyrazol-4-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(imidazo[1,2-a]pyridin-6-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(imidazo[1,2-a]pyridin-6-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(6-(dimethylamino)pyridine-3-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(isoxazol-3-yl)phenylamino)pyrimidine-5-carboxamide; 4-(4-(4H-1,2,4-triazol-4-

ylphenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide; 4-(3-(4H-1,2,4-triazol-4-ylphenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(isoxazol-3-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(5-methylisoxazol-3-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(2,3-dihydrobenzofuran-5-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(benzo[d][1,3]dioxol-4-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(benzo[d][1,3]dioxol-5-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(quinolin-4-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(quinolin-8-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(quinolin-5-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-methyl-4-(2H-1,2,3-triazol-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-methyl-4-(1H-pyrazol-1-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(2H-1,2,3-triazol-2-yl)-4-(trifluoromethyl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(1H-1,2,3-triazol-1-yl)-4-trifluoromethyl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-fluoro-4-(2H-1,2,3-triazol-2-yl)phenylamino)pyrimidine-5-carboxamide; 4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-((3R,4R)-3-aminotetrahydro-2H-pyran-4-ylamino)pyrimidine-5-carboxamide; 4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-((3S,4S)-4-aminotetrahydro-2H-pyran-3-ylamino)pyrimidine-5-carboxamide; 4-(3-(1H-pyrazol-1-yl)phenylamino)-2-((3R,4R)-3-aminotetrahydro-2H-pyran-4-ylamino)pyrimidine-5-carboxamide; 2-((3R,4R)-3-aminotetrahydro-2H-pyran-4-ylamino)-4-(3-

(pyrimidin-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-bromo-3-(2H-1,2,3-triazol-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-bromo-5-(2H-1,2,3-triazol-2-yl)phenylamino)pyrimidine-5-carboxamide; 2-((1R,2S)-2-aminocyclohexylamino)-4-(4-chloro-3-(2H-1,2,3-triazol-2-yl)phenylamino)pyrimidine-5-carboxamide and 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-chloro-5-(2H-1,2,3-triazol-2-yl)phenylamino)pyrimidine-5-carboxamide, and a pharmaceutically acceptable salt thereof.


15. A compound according to claim 1 having the formula:



;

or a pharmaceutically acceptable salt thereof.

16. A compound according to claim 1 having the formula:



;

or a pharmaceutically acceptable salt thereof.

17. A composition comprising a compound of any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier or diluent.

18. An *in vitro* method for inhibiting syk or JAK kinase or a signal transduction pathway mediated at least in part by syk kinase activity.

19. A composition according to claim 17 for treating a condition or disorder mediated at least in part by syk kinase activity in a subject.

20. A composition according to claim 19, wherein the condition or disorder is selected from the group consisting of cardiovascular disease, inflammatory disease and autoimmune disease and cell proliferative disorder.

21. A composition according to claim 20, wherein said cardiovascular disease is selected from the group consisting of restenosis, thrombosis, immune thrombocytopenic purpura, heparin induced thrombocytopenia, dilated cardiomyopathy, sickle cell disease, atherosclerosis, myocardial infarction, vascular inflammation, unstable angina and acute coronary syndromes.

22. A composition according to claim 20, wherein said inflammatory disease is selected from the group consisting of allergy, asthma, rheumatoid arthritis, B Cell mediated diseases such as Non Hodgkin's Lymphoma, anti phospholipid syndrome, lupus, psoriasis, multiple sclerosis and end stage renal disease.

23. A composition according to claim 20, wherein said cardiovascular disease is selected from the group consisting of thrombosis, immune thrombocytopenic purpura, and heparin induced thrombocytopenia.

24. A composition according to claim 20, wherein said inflammatory disease is rheumatoid arthritis or Non Hodgkin's Lymphoma.

25. A composition according to claim 20, wherein said sickle cell disease is selected from the group consisting of sickle cell anemia, sickle-hemoglobin C disease, sickle beta-plus thalassemia, and sickle beta-zero thalassemia.

26. A composition according to claim 20, wherein said immune-related disease is selected from the group consisting of a T-cell mediated disease, an autoimmune disease, host versus graft rejection, graft versus host rejection, a Type IV hypersensitivity reaction and allograft rejection.

27. A composition according to claim 20, wherein said autoimmune disease is selected from the group consisting of hemolytic anemia, immune thrombocytopenic purpura, multiple sclerosis, Sjogren's syndrome. diabetes, rheumatoid arthritis, lupus and psoriasis.

28. A composition according to claim 20, wherein said wherein said cell proliferative disorder is leukemia, a lymphoma, myeloproliferative disorders, hematological malignancies, and chronic idiopathic myelofibrosis.

29. A composition according to claim 20, wherein said disorder is acute myeloid leukemia, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma.

30. A composition according to claim 20, wherein said condition or disorder is asthma.

31. A composition according to claim 20, wherein said condition or disorder is non-Hodgkin's Lymphoma.

32. A composition according to claim 20, wherein said condition or disorder is arthritis.

33. A composition according to claim 20, wherein said condition or disorder is lupus.

34. A composition according to claim 20 for use in combination with another agent useful for treating said condition or disorder.

35. A kit comprising a composition of claim 17, packaging and instructions for use.